Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections.
Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections.
复制标题
DOI：
10.3389/fmicb.2016.00450
复制
发表时间：
2016
影响因子：
5.2
通讯作者：
Zaraket H
中科院分区：
文献类型：
--
作者：
Alame MM;Massaad E;Zaraket H
帕拉米韦是一种新型的环戊烷类神经氨酸酶抑制剂。它于2014年12月被美国食品和药物管理局批准用于治疗18岁及以上患者的急性无并发症流感。在批准前的几个月里，该药物在2009年H1N1流感大流行期间根据紧急使用授权在临床上可用。帕拉米韦对人甲型和B型流感病毒分离株以及新出现的具有大流行潜力的流感病毒株高度有效。临床试验表明，该药物在成人和儿童人群中耐受性良好。不良事件通常为轻度至中度，频率与接受安慰剂的患者相似。常见的副作用包括胃肠道疾病和中性粒细胞计数减少，但具有自限性。帕拉米韦通过静脉途径单次给药，为重症患者或无法耐受其他给药途径的患者提供了一种有价值的治疗替代方案。在日本儿科人群中成功的临床试验和上市后数据支持帕拉米韦在该人群中的安全性和有效性，因为其他抗病毒药物给药可能不可行。
Peramivir is a novel cyclopentane neuraminidase inhibitor of influenza virus. It was approved by the Food and Drug Administration in December 2014 for treatment of acute uncomplicated influenza in patients 18 years and older. For several months prior to approval, the drug was made clinically available under Emergency Use authorization during the 2009 H1N1 influenza pandemic. Peramivir is highly effective against human influenza A and B isolates as well as emerging influenza virus strains with pandemic potential. Clinical trials demonstrated that the drug is well-tolerated in adult and pediatric populations. Adverse events are generally mild to moderate and similar in frequency to patients receiving placebo. Common side effects include gastrointestinal disorders and decreased neutrophil counts but are self-limiting. Peramivir is administered as a single-dose via the intravenous route providing a valuable therapeutic alternative for critically ill patients or those unable to tolerate other administration routes. Successful clinical trials and post-marketing data in pediatric populations in Japan support the safety and efficacy of peramivir in this population where administration of other antivirals might not be feasible.